Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Phase 2

Recruiting

• Conditions: Acute Stroke; Stroke; Ischemic Stroke
• Interventions: Drug: Recombinant human tissue kallikrein; Other: Placebo for DM199 Solution for Injection

• Registration Number: NCT05065216
• Lead Sponsor: DiaMedica Therapeutics Inc

Brief Summary

This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.

Detailed Description

This is a Phase 2/3 Adaptive Design, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial). Participants with AIS will be randomized 1:1 to DM199 or placebo. DM199 will be administered as a single intravenous (IV) dose (0.5 μg/kg; not to exceed 50 μg) followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21. The duration of each individual's participation in the study will be approximately 90 days from the time of initial treatment to completion of all study activities.

A formal interim analysis will be conducted after 200 participants complete their Day 90 assessment in Part A. The purposes of this interim analysis are to assess safety, allow early stopping of the study for futility, or continuing the study with a revised final sample up to a maximum of 728 participants.

Study Timeline

• Study First Submitted: 2021-09-03
• Study First Submitted QC: 2021-09-29
• Study First Posted: 2021-10-04
• Study Start: 2021-11-07
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-29
• Last Update Posted: 2025-05-02
• Primary Completion: 2026-12
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 728

Inclusion Criteria

1. Participant is between 18 and 90 years of age inclusive.

2. Participant weight is 40 kg to 166 kg inclusive.

3. Participant to be randomized and treatment initiated within 24 hours of last known normal/AIS stroke onset.

4. Participant has NIHSS ≥5 and ≤15 at approximately the time of randomization. This criterion also applies to participants who meet the following conditions:

   • The participant initially presents with an NIHSS score below 5 but clinically worsens, including cases of progressing stroke / stroke-in-evolution, resulting in a subsequent persistent NIHSS score of ≥5 and ≤15; and
   • Participant meets all other inclusion and exclusion criteria, including repeat brain imaging to rule out hemorrhagic transformation.

5. Participant had a pre-morbid mRS score of 0 to 1 (mRS score prior to AIS) as stated by participant or participant's representative.

6. If participant has received fibrinolytic treatment for AIS within 4.5 hours of last know normal/AIS stoke onset and at least 6 hours after completing fibrinolytic treatment, and the participant meets all of the following criteria:

   • Participant's initial NIHSS score prior to fibrinolytics was ≤15; and
   • At least six hours after fibrinolytics, the participant has NIHSS score of ≥5 and ≤15 with a persistent deficit; and
   • The participant's NIHSS score showed less than a 4-point improvement, or worsened, after receiving fibrinolytics; and
   • Participant meets all other inclusion and exclusion criteria including repeat brain imaging to rule out hemorrhagic transformation.

7. Participant and/or legally authorized representative is able to provide informed consent.

8. Participant is willing and able to comply with the study protocol, in the Investigator's judgment.

Exclusion Criteria

1. At screening, or with repeat imaging (see Inclusion 4 and 6), participant has imaging confirmed hemorrhage stroke.

2. Participant has image findings with symptomatic large vessel occlusion at one or more of the following locations: Intracranial carotid I/T/L or M1 segment MCA, vertebral or basilar artery (BA).

3. Participant has large core of established infarction defined as ASPECTS 0-5.

4. Participant has or will receive MT for their current AIS.

5. Participant has suspected or confirmed extracranial arterial dissection.

6. Participant has imaging findings and/or symptoms consistent with a brain stem or cerebellar stroke. Posterior cerebral artery strokes without any associated brain stem or cerebellar involvement are allowable.

7. Participant has any recorded SBP <100 mmHg or MAP <65 mmHg; MAP = DBP + [1/3 (SBP - DBP)] (measured with noninvasive BP cuff type monitor) after stroke symptom onset and prior to randomization.

8. Participant is currently prescribed angiotensin-converting enzyme inhibitor (ACEi) and is unable or unwilling to convert to another antihypertensive pharmacological treatment through Day 29 ±1 day (8 days after last treatment).

9. Participant is currently prescribed an ACEi, and the last dose of the ACE inhibitor medication is reported to have been taken < 24 hours before start of IV study drug infusion as stated by participant or participant's representative.

10. Participant has a history of clinically significant allergic reactions such as angioedema or anaphylaxis requiring hospitalization.

11. Participant has a diagnosis or suspected diagnosis of hereditary angioedema (HAE) or is taking or prescribed medications commonly used as prophylaxis/treatment of HAE, such as C1-esterase inhibitors (Cinryze, Berinert, Ruconest, Haegarda), Danazol, kallikrein inhibitors (Ecallantide, Berotralstat, Lanadelumab), Bradykinin B2 Receptor Antagonists (Icatibant), or other medication designed to influence the kallikrein-kinin system.

12. Life expectancy estimated at ≤1 year prior to enrollment.

13. Participant has clinical evidence of an active infection at the time of enrollment requiring parenteral treatment or hospitalization to monitor or manage the infection.

    NOTE: Treatment of uncomplicated infections with oral antibiotics would not be an exclusion (for example, the treatment of uncomplicated urinary tract infections or sinus infections with oral antibiotics would not be exclusionary).

14. Participant has known alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency).

15. Participant is pregnant or nursing. NOTE: Participants who agree to stop nursing may be considered for inclusion at the discretion of the Investigator.

16. Participants of child-bearing potential must agree to use medically acceptable contraceptive measures to prevent pregnancy. All participants of childbearing potential (defined as sexually mature participants who have had menses within the preceding 24 months and have not undergone permanent sterilization methods such as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) must have a negative serum pregnancy test performed locally at screening. Participants of childbearing potential must agree not to attempt to become pregnant or undergo in vitro fertilization. If participating in sexual activity that could lead to pregnancy, participants must use 2 reliable methods (1 per partner is acceptable) of contraception simultaneously while receiving protocol-specified medication and during the study follow-up period.

    Participants participating in sexual activity must agree to use, or for their partner to use highly effective birth control methods (those with a failure rate of less than 1% per year when used consistently and correctly) until they have completed the study (after the Day 90 visit). Such methods include:

    • Combined (estrogen and progesterone containing) hormonal oral, intravaginal, or transdermal contraception associated with the inhibition of ovulation
    • Progesterone-only oral, injectable, or implantable hormonal contraception associated with the inhibition of ovulation
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomized partner
    • Sexual abstinence Participants who are not of reproductive potential (who have been postmenopausal for more than 24 consecutive months or have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) are not required to use contraception.

    Participants are prohibited from sperm donation. NOTE: A negative serum pregnancy test will be documented during screening if a participant is of child-bearing potential.

17. Participant is currently participating in or has participated in a study using an investigational device or drug or received an investigational drug or investigational use of a licensed drug within 30 days prior to screening.

18. Participant does not have sufficient venous access for infusion of study treatment or blood sampling.

19. Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits.

20. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
DM199	Recombinant human tissue kallikrein	DM199 administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21.
Placebo for DM199 Solution for Injection	Placebo for DM199 Solution for Injection	Placebo administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21.

Primary Outcome Measures

Name	Time	Method
Stroke Recovery	Day 90	Stroke recovery as defined by participants with excellent functional outcomes at Day 90 as assessed via the Modified Rankin Score (mRS \[dichotomized\]), mRS scores of 0 or 1 represent responders, scale range of 0-6.; The mRS (Modified Rankin Scale) is a single-item, clinician-reported measure of functional disability in participants with AIS. Scores range in grade from 0 (no symptoms at all) to 6 (participant death).

Secondary Outcome Measures

Name	Time	Method
Effect on Disability	Day 90	Assessment of effect on disability across the full spectrum of AIS by examining the distribution of mRS (shift) scores (scale range = 0 to 6) at Day 90. The mRS (Modified Rankin Scale) is a single-item, clinician-reported measure of functional disability in participants with AIS. Scores range in grade from 0 (no symptoms at all) to 6 (participant death).
Independent Function	Day 90	Proportion of participants achieving independent function (able to look after their own affairs without assistance) with or without minor disability at Day 90 assessed as mRS 0-2 (dichotomized) mRS scores of 0, 1 or 2 represent responders, scale range of 0-6. The mRS (Modified Rankin Scale) is a single-item, clinician-reported measure of functional disability in participants with AIS. Scores range in grade from 0 (no symptoms at all) to 6 (participant death).
Mortality Rate	Day 90	Mortality rate as defined by event rate (%) for mortality over 90 days.
Neurological Outcome	Day 90	Proportion of participants achieving an excellent neurological outcome defined by National Institute of Health Stroke Scale (NIHSS)= 0-1 (dichotomized) (NIHSS scores of 0 or 1, scale range 0 to 42) at Day 90.; The National Institute of Health Stroke Scale (NIHSS) is a clinician-reported measure used to rate the severity of strokes, namely disability and recovery after acute stroke. The scale is comprised of 11 items with item scores ranging from 0 to 4. Total scores range from 0 to 42, with higher scores indicating increased severity.
Functional Independence	Day 90	Proportion of participants achieving an excellent functional independence in activities of daily living defined by Barthel Index score (dichotomized) greater than or equal to 5 (scale range 0 to 100) at Day 90.; The Barthel Index (BI) is a 10-item scale assessing activities of daily living and functional disability. Each item is scored in increments of 5 points (0, 5, 10, or 15) and the individual items are summed to produce a total score between 0 and 100, with higher scores representing more optimal performance (100 = fully independent) and lower scores representing inferior performance (0 = totally dependent).
AIS Recurrence	Day 90	Recurrent AIS as defined by proportion of participants who experience a recurrent AIS by Day 90 as assessed by a new, persistent neurological deficit attributable to cerebrovascular ischemia. Imaging findings, if available, should support the diagnosis.

Trial Locations

Locations (35)

Ascension Via Christi Hospitals Wichita Inc.; 🇺🇸 Wichita, Kansas, United States

Gulf Health Hospitals d/b/a Thomas Hospital; 🇺🇸 Fairhope, Alabama, United States

Glendale Adventist Medical Center d/b/a Adventist Health Glendale; 🇺🇸 Glendale, California, United States

Kaiser Permanente Los Angeles Medical Center; 🇺🇸 Los Angeles, California, United States

Memorialcare Long Beach Medical Center; 🇺🇸 Torrance, California, United States

HCA Florida - JFK Medical Center; 🇺🇸 Atlantis, Florida, United States

Sarasota Memorial Hospital; 🇺🇸 Sarasota, Florida, United States

Tampa General Hospital (TGH) - The Stroke Center; 🇺🇸 Tampa, Florida, United States

OSF HealthCare Saint Francis Medical Center; 🇺🇸 Peoria, Illinois, United States

Community Hospital - MacArthur; 🇺🇸 Munster, Indiana, United States

Medstar Franklin Square Medical Center; 🇺🇸 Baltimore, Maryland, United States

Trinity Health Grand Rapids Hospital; 🇺🇸 Grand Rapids, Michigan, United States

Abbott Northwestern Hospital; 🇺🇸 Minneapolis, Minnesota, United States

SSM Health DePaul Hospital - St Louis; 🇺🇸 Bridgeton, Missouri, United States

The University of New Mexico - School of Medicine; 🇺🇸 Albuquerque, New Mexico, United States

Northwell Health Physician Partners - Neurology at Lenox Hill; 🇺🇸 New York, New York, United States

Miami Valley Hospital; 🇺🇸 Dayton, Ohio, United States

The Clinical Neuroscience Institute; 🇺🇸 Dayton, Ohio, United States

Mercy Health - St. Vincent Medical Center; 🇺🇸 Toledo, Ohio, United States

The University of Oklahoma Health Sciences Center; 🇺🇸 Oklahoma City, Oklahoma, United States

Ascension St. John; 🇺🇸 Tulsa, Oklahoma, United States

Oregon Health & Science University; 🇺🇸 Portland, Oregon, United States

The Hospital of the University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Prisma Health-Greenville Memorial Hospital; 🇺🇸 Greenville, South Carolina, United States

Erlanger Hospital; 🇺🇸 Chattanooga, Tennessee, United States

Chattanooga Center for Neurologic Research; 🇺🇸 Chattanooga, Tennessee, United States

Ballad Health; 🇺🇸 Johnson City, Tennessee, United States

Houston Methodist Neurological Institute; 🇺🇸 Houston, Texas, United States

Memorial Hermann Hospital, Texas Medical Center; 🇺🇸 Houston, Texas, United States

Vancouver General Hospital; 🇨🇦 Vancouver, British Columbia, Canada

West Georgia Medical Center LTD; 🇬🇪 Kutaisi, Georgia

Israel-Georgia Medical Research Clinic-Healthycore LTD; 🇬🇪 Tbilisi, Georgia

New Hospitals LTD; 🇬🇪 Tbilisi, Georgia

Pineo Medical Ecosystem LTD; 🇬🇪 Tbilisi, Georgia

JSC K. Eristavi National Center of Experimental and Clinical Surgery; 🇬🇪 Tbilisi, Georgia